Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, ...

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

Matthew Herper covers medical innovation — both its promise and its perils. Eli Lilly will pay up to $2.4 billion to acquire Orna Therapeutics, a biotechnology firm that is developing a technology to ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Global pharmaceutical firm Eli Lilly and Co. will invest $3.5 billion to build a manufacturing plant in Upper Macungie Township that is expected to create 850 jobs. “This is the largest single project ...

For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...

On the Jan. 5, 2026, episode of The Morning Filter podcast, Morningstar Chief US Market Strategist Dave Sekera commented on what the Food and Drug Administration’s approval of Novo Nordisk’s NVO ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space of oral obesity therapies. The latest partnership will see Lilly pass ...

This is read by an automated voice. Please report any issues or inconsistencies here. Evangeline Lilly says much of her brain is “functioning at a decreased capacity” after her traumatic brain injury ...